2019-02870. Importer of Controlled Substances Registration  

  • Start Preamble

    ACTION:

    Notice of registration.

    SUMMARY:

    The registrant listed below has applied for and has been granted registration by the Drug Enforcement Administration (DEA) as an importer of schedule II controlled substances.

    End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    The company listed below applied to be registered as an importer of a basic class of controlled substance. Information on the previously published notice is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for this notice.

    CompanyFR docketPublished
    Myoderm83 FR 66751December 27, 2018.

    The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrant to import the applicable basic class of schedule II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

    Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule II controlled substances to the above listed company.

    Start Signature

    Dated: February 11, 2019.

    John J. Martin,

    Assistant Administrator.

    End Signature End Supplemental Information

    [FR Doc. 2019-02870 Filed 2-20-19; 8:45 am]

    BILLING CODE 4410-09-P

Document Information

Published:
02/21/2019
Department:
Drug Enforcement Administration
Entry Type:
Notice
Action:
Notice of registration.
Document Number:
2019-02870
Pages:
5478-5478 (1 pages)
Docket Numbers:
Docket No. DEA-392
PDF File:
2019-02870.pdf